Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Abbott Laboratories recently received FDA clearance for Tendyne, its transcatheter mitral valve replacement system. The news comes on the heels of Edwards Lifesciences Corp. securing a CE mark for its ...

Bardet-Biedl syndrome (BBS) is a group of rare autosomal recessive ciliopathies characterized by dysfunction of primary cilia, which affects multiple organ systems and leads to early-onset obesity, ...

Bioage Labs Inc. has completed IND-enabling studies for BGE-102, a structurally novel, orally available small-molecule NLRP3 ...

Voltron Therapeutics Inc. has reported data from a study evaluating VTX-0P4.

Silexion Therapeutics Corp. has released preclinical data demonstrating the efficacy of its next-generation RNA interference ...

For the second time in as many months, the lack of statistically significant overall survival data sent shares of Summit Therapeutics Inc. sliding, despite otherwise positive findings for PD-1/VEGF ...

The U.S. Department of Justice is reshuffling its enforcement focus for the coming three years per a May 12 memo attributed to Matthew Galeotti, director of the department’s criminal division.

In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.

CSPC Pharmaceutical Group Ltd. on May 30 disclosed that the company was engaged in ongoing negotiations with unnamed, independent third parties regarding three license deals and collaborations that ...

Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related deaths worldwide due to lack of effective diagnosis at early stages and limited comprehension of its pathogenesis, thus ...

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified radiolabeled or nonradiolabeled compounds acting as fibroblast activation protein-α (FAPα) inhibitors reported to be useful for the ...